Építés alatt – nem éles oldal
Belépés
Felfüggesztve3. fázis

The NIPA Study Naloxegol Administration to Prevent Opioids Induced Gastrointestinal Motility Disturbance in Brain Injured PAtients

A legfontosabb adatok

Ki végzi
University Hospital, Brest
Hol
Franciaország10 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Felfüggesztve
Fázis
3. fázis
Résztvevők
370 fő, tervezett
Kezdés
2022. márc. 15.
Várható befejezés
2028. ápr. 26.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • Naloxegol
  • Placebo
A regiszteradat frissítve
2026. június 16.
Miért állt le
interim analysis - Results ongoing

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 22 feltétel megnézéseKevesebb

Ki vehet részt

  • Age ≥ to 18 years old
  • Admission to intensive care unit for traumatic brain injury or subarachnoid hemorrhage without other life-threatening injury
  • Patients under sedation with administration of opiate-agonists, μ receptor agonists (Sufentanil, Fentanyl, Remifentanil, Morphine) for less than 24 hours
  • Expected duration of invasive mechanical ventilation and sedation of 48 hours or more
  • Intracranial pressure monitoring
  • Enteral feeding by oro / nasogastric tube
  • Affiliated or beneficiary of the French social security system

Ki nem vehet részt

  • Patient who received opioids for more than 24 hours
  • Concomitant treatment with a strong or moderate inhibitory effect of CYP 3A4 (For example: clarithromycin, ketaconazole, itraconazole, telithromycin, ritonavir, indinavir, saquinavir) or with a strong inducing effect (carbamazepin, rifampicin, millepertuis)
  • Concomitant treatment with vascular endothelial growth factor (VEGF) inhibitor
  • Patient with refractory intracranial hypertension at the time of inclusion: intracranial hypertension requiring therapy other than analgo-sedation (thiopental, targeted temperature management, decompressive craniectomy)
  • Risk of digestive perforation:; history of peptic ulcer; Crohn's disease; Ogilvie syndrome; acute diverticulitis; infiltrating gastrointestinal tumor; recurrent or advanced ovarian cancer; peritoneal metastasis; recent abdominal trauma with risk of digestive perforation
  • Allergy to Naloxegol or one of its excipients
  • History of clinically important alterations of the blood-brain barrier: primary brain tumors, metastasis or other inflammatory pathologies in the CNS, active multiple sclerosis, Alzheimer's disease at an advanced stage
  • Acute or chronic renal failure with creatinine clearance <60ml / min
  • Recent history of myocardial infarction within the past 6 months, symptomatic congestive cardiovascular disease, QT ≥ 500 msec
  • Known or suspected acute gastrointestinal obstruction
  • Patient with a medical decision for rapid palliative care
  • Pregnancy and / or breastfeeding
  • Child Pugh C stage cirrhosis
  • Patient under legal protection or deprived of liberty
  • Patient with another life-threatening injury

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

Impaired gastrointestinal transit (IGT) especially constipation, is common among patients under mechanical ventilation, occurring in up to 80 % of the patients during the first week, and has been associated with worse outcome in intensive care unit (ICU). Although IGT in critically ill patients is multifactorial and some components are due to complex disease, there is increasing evidence that exogenous opioids contribute to bowel dysmotility.

A teljes eredeti leírásKevesebb

Sedatives and especially opioids are largely used in the brain injured population to control intracranial pression, reduce metabolic rate, manage or prevent seizures, and improve mechanical ventilator synchrony. Therefore, brain injured patients are particularly at risk to develop IGT. The occurrence of IGT is associated with adverse outcomes in intensive care unit. Both gastric reflux and impaired peristaltic contractions are associated with ventilator-acquired pneumonia.

The actual challenge is to prevent motility disorders before it occurs. A preventive strategy could in turn reduce the occurrence of complications related to impaired gastrointestinal transit such as ventilator-acquired pneumonia, bacteremia etc. It could also reduce the complications of feed intolerance and thus reduce morbidity and mortality in ICU.

Naloxegol is a polyethylene glycol derivative of naloxol, which is a derivative of naloxone and a peripherally acting µ-opioid receptor antagonist. Contrary to naloxone, naloxegol has a very low penetration into the central nervous system, therefore it could be a relevant option for ileus prevention without the risk of impaired sedation.

The aim of our study is to assess the efficacy of the administration of naloxegol on the onset of early constipation and early ventilator-acquired pneumonia in brain injured patients receiving opioids for analgosedation.

A vizsgálat 2 csoportja

  • NaloxegolA vizsgált kezelés

    Administration of Naloxegol 25 mg per day by nasogastric tube (NG) or orogastric tube (OG). The administration should be started within the first 24 hours after the patient is admitted to intensive care unit and continued for the duration of the administration of the morphine derivative and until 48 hours after its discontinuation. Management of constipation and gastroparesis according to the recommendations.

  • PlaceboPlacebo, összehasonlításként

    Administration of the placebo according to the same procedures as the experimental arm.

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
The NIPA Study: A Randomized Double-blind Control Clinical Trial Naloxegol Administration to Prevent Opioids Induced Gastrointestinal Motility Disturbance in Brain Injured PAtients
A regiszteradat frissítve
2026. június 16.